FSCN1 levels were measured in the serum samples of 27 ACC patients and compared with measurements obtained in the serum samples of non-tumoral obese/T2D patients (n=8) and non-tumoral/non-obese/non-T2D subjects (n=4). Here, FSCN1 is linked to type 2 diabetes mellitus.